UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

Lung cancer (Amsterdam, Netherlands), 2019-01, Vol.127, p.153-163

2019

Volltextzugriff (PDF)

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

European journal of cancer (1990), 2020-03, Vol.128, p.17-26

2020

Volltextzugriff (PDF)

The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient"

Human vaccines & immunotherapeutics, 2021-07, Vol.17 (7), p.1930-1934

2021

Volltextzugriff (PDF)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.57-57, Article 57

2019

Volltextzugriff (PDF)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials

Human vaccines & immunotherapeutics, 2022-05, Vol.18 (3), p.1902723-1902723

2022

Volltextzugriff (PDF)

Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta–lesion attenuation difference (ALAD) on contrast-enhanced CT

Radiologia medica, 2020-12, Vol.125 (12), p.1280-1287

2020

Volltextzugriff (PDF)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

Therapeutic Advances in Medical Oncology, 2017-10, Vol.9 (10), p.627-636

2017

Volltextzugriff (PDF)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920952994-1758835920952994

2020

Volltextzugriff (PDF)

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Journal for immunotherapy of cancer, 2019-04, Vol.7 (1), p.99-99, Article 99

2019

Volltextzugriff (PDF)

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

Scientific reports, 2019-09, Vol.9 (1), p.13218-13218, Article 13218

2019

Volltextzugriff (PDF)

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

Therapeutic Advances in Medical Oncology, 2020, Vol.12, p.1758835920915303-1758835920915303

2020

Volltextzugriff (PDF)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib

Therapeutic advances in medical oncology, 2022-02, Vol.14, p.17588359221079580-17588359221079580

2022

Volltextzugriff (PDF)

Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of "palateau"

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2351669-2351669

2024

Volltextzugriff (PDF)

Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review

Current research in pharmacology and drug discovery, 2023-01, Vol.4, p.100146, Article 100146

2023

Volltextzugriff (PDF)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis

Therapeutic advances in urology, 2021, Vol.13, p.17562872211053189-17562872211053189

2021

Volltextzugriff (PDF)

Axitinib dose titration: what's the limiting factor?

The lancet oncology, 2013-11, Vol.14 (12), p.1152-1154

2013

Volltextzugriff (PDF)

Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study

Scientific reports, 2024-02, Vol.14 (1), p.4949-4949, Article 4949

2024

Volltextzugriff (PDF)

AR-V7 and prostate cancer: The watershed for treatment selection?

Cancer treatment reviews, 2016-02, Vol.43, p.27-35

2016

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives

Cancers, 2022-02, Vol.14 (5), p.1245

2022

Volltextzugriff (PDF)

The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study

Therapeutic advances in urology, 2023-01, Vol.15, p.17562872231187216-17562872231187216

2023

Volltextzugriff (PDF)

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)

Lung cancer (Amsterdam, Netherlands), 2017-02, Vol.104, p.24-30

2017

Volltextzugriff (PDF)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)

International journal of molecular sciences, 2023-01, Vol.24 (2), p.1096

2023

Volltextzugriff (PDF)

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Journal of translational medicine, 2022-09, Vol.20 (1), p.435-7, Article 435

2022

Volltextzugriff (PDF)

1 – 25 von 357

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(343)
Mit Volltextzugriff
(292)

Publikationsform

Artikel
(355)
Berichte
(1)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(249)
Life Sciences & Biomedicine
(245)
Oncology
(183)
Humans
(161)
Immunotherapy
(112)
Male
(82)
Renal Cell Carcinoma
(76)
Female
(75)
Aged
(66)
Metastasis
(65)
Middle Aged
(63)
Kidney Cancer
(61)
Retrospective Studies
(59)
Immune Checkpoint Inhibitors
(49)
Carcinoma, Renal Cell - Drug Therapy
(47)
Immunology
(47)
Treatment Outcome
(45)
Kidney Neoplasms - Drug Therapy
(44)
Patients
(43)
Tumors
(42)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient"

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials

Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta–lesion attenuation difference (ALAD) on contrast-enhanced CT

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib

Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of "palateau"

Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis

Axitinib dose titration: what's the limiting factor?

Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study

AR-V7 and prostate cancer: The watershed for treatment selection?

Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives

The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Suchergebnisse filtern